Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Potential seminal transport of pharmaceuticals to the conceptus

Delise, Anthony and Scialli, Anthony and Bailey, Graham and Beyer, Bruce and Bruck Bogh, Ingrid and Breslin, William and Chen, Connie and Moffat, Graeme and Hui, Julia and Stewart, Jane and Thompson, Kary (2015) Potential seminal transport of pharmaceuticals to the conceptus. Reproductive Toxicology, 58. pp. 213-221.

Abstract

Small molecule pharmaceutical products are assumed to reach concentrations in semen similar to those in blood plasma. Exposure modeling for these small-molecule products assumes a daily dose of 5 mL of semen and 100% absorption from the vagina with distribution to the conceptus through the maternal systemic circulation. Monoclonal antibody drugs are present in semen at concentrations about 2% or less of those in blood, and the modeling used for small molecules will over-estimate the possibility of conceptus exposure to immunoglobulins. It is not known whether peptide products reach semen, but peptide medications are destroyed by vaginal peptidases, and conceptus exposure is predicted to be minimal. Theoretical exposure routes to pharmaceuticals that might result in exposure of the conceptus greater than that of maternal systemic exposures include direct access through the cervical canal, adsorption to sperm for carriage into the oocyte, and direct delivery from the vaginal veins or lymphatics to the uterine artery. There is some evidence for direct access to the uterus for progesterone, terbutaline, and danazol, but the evidence does not involve exposures during pregnancy in most instances. Studies in mice, rats, rabbits, and monkeys do not suggest that exposure to small molecule pharmaceuticals in semen imposes risks to the conceptus beyond those that can be predicted using modeling of systemic maternal exposure. Monoclonal antibody and peptide exposure in semen does not pose a risk to the conceptus.

Item Type: Article
Keywords: Semen; Male-mediated pregnancy effects; Monoclonal antibodies; Peptides; Pharmacueticals
Date Deposited: 01 Dec 2015 00:45
Last Modified: 01 Dec 2015 00:45
URI: https://oak.novartis.com/id/eprint/26860

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.